People relying on popular weight-loss injections face rapid weight regain once treatment ceases, prompting recommendations for sustained, long-term support, according to new research.
A University of Oxford study, published in the British Medical Journal, analysed 37 trials involving over 9,000 individuals. Participants, who were treated with medications such as semaglutide (Wegovy) and tirzepatide (Mounjaro) for an average of 10 months, were followed for approximately eight months after stopping their course.
